89 related articles for article (PubMed ID: 30767719)
1. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Gini J; Olagunju A; Dickinson L; Waitt C; Neary M; Else LJ; Siccardi M; Khoo S
Pharmacogenomics; 2019 Mar; 20(4):217-223. PubMed ID: 30767719
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.
Seifert SM; Chen X; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Clayton C; Austin G; Palmer BE; Zheng JH; Klein B; Kerr BJ; Guida LA; Rower C; Rower JE; Kiser JJ; Bushman LR; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2016; 32(10-11):981-991. PubMed ID: 27526873
[TBL] [Abstract][Full Text] [Related]
3. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
4. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
[TBL] [Abstract][Full Text] [Related]
6. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
Bertrand J; Barrail-Tran A; Fayette L; Savic R; Goujard C; Teicher E; Barau C; Pruvost A; Taburet AM; Mentré F; Verstuyft C
Antimicrob Agents Chemother; 2023 May; 67(5):e0233918. PubMed ID: 37098914
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Dumond JB; Francis O; Cottrell M; Trezza C; Prince HM; Mollan K; Sykes C; Torrice C; White N; Malone S; Wang R; Van Dam C; Patterson KB; Hudgens MG; Sharpless NE; Forrest A
Antivir Ther; 2016; 21(5):441-5. PubMed ID: 26731175
[TBL] [Abstract][Full Text] [Related]
11. p16
Dumond JB; Collins JW; Cottrell ML; Trezza CR; Prince H; Sykes C; Torrice C; White N; Malone S; Wang R; Patterson KB; Sharpless NE; Forrest A
CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):120-127. PubMed ID: 28019088
[TBL] [Abstract][Full Text] [Related]
12. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
[TBL] [Abstract][Full Text] [Related]
13. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
14. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
15. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
[TBL] [Abstract][Full Text] [Related]
16. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
Figueroa DB; Madeen EP; Tillotson J; Richardson P; Cottle L; McCauley M; Landovitz RJ; Andrade A; Hendrix CW; Mayer KH; Wilkin T; Gulick RM; Bumpus NN
AIDS Res Hum Retroviruses; 2018 May; 34(5):421-429. PubMed ID: 29455571
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Floridia M; Pinnetti C; Ravizza M; Masuelli G; Personeni C; Sansone M; Degli Antoni A; Guaraldi G; Spinillo A; Tassis B; Dalzero S; Liuzzi G; Tamburrini E
J Acquir Immune Defic Syndr; 2018 May; 78(1):99-104. PubMed ID: 29406430
[TBL] [Abstract][Full Text] [Related]
18. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
[TBL] [Abstract][Full Text] [Related]
20. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]